-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NNV1 in Glioblastoma Multiforme (GBM)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NNV1 in Glioblastoma Multiforme (GBM) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NNV1 in Glioblastoma Multiforme (GBM) Drug Details: NNV1 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ADCT-901 in Bile Duct Cancer (Cholangiocarcinoma)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. ADCT-901 in Bile Duct Cancer (Cholangiocarcinoma) Drug Details: ADCT-901 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Navitoclax Dihydrochloride in Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Navitoclax Dihydrochloride in Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis) Drug Details: Navitoclax (ABT-263, RG7433) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Retifanlimab in Sarcomas
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Retifanlimab in Sarcomas report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Retifanlimab in Sarcomas Drug Details: Retifanlimab (Zynyz) is a humanized IgG4 kappa...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – EI-001 in Hemophagocytic Lymphohistiocytosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - EI-001 in Hemophagocytic Lymphohistiocytosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. EI-001 in Hemophagocytic Lymphohistiocytosis Drug Details: EI-001 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AP-303 in Diabetic Nephropathy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AP-303 in Diabetic Nephropathy report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AP-303 in Diabetic Nephropathy Drug Details: AP-303 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SNV-0 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SNV-0 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SNV-0 in Solid Tumor Drug Details: SVF-CAL1 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Liothyronine Sodium Sr in Hypothyroidism
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Liothyronine Sodium Sr in Hypothyroidism Drug Details: Liothyronine sodium (K-114) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NNV1 in Glioblastoma Multiforme (GBM)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. NNV1 in Glioblastoma Multiforme (GBM) Drug Details: NNV1 is under development for the treatment of...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Cell Therapy For Coronavirus Disease 2019 (COVID-19), Alopecia Areata And Type 1 Diabetes in Alopecia Areata
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cell Therapy For Coronavirus Disease 2019 (COVID-19), Alopecia Areata And Type 1 Diabetes in Alopecia Areata report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data....